Sign in with your email address username.

×

[Comment] Cardiac gene therapy: a call for basic methods development

In 1995, when I entered the specialty of cardiac gene therapy, the principal limitation was the inability to reliably transfer genes to the cardiac ventricles. Soon after that time, a series of angiogenesis gene therapy clinical trials did not show efficacy in randomised testing.1,2 Investigation of the delivery methods used in those studies verified that insufficient gene transfer was a significant factor.3 In 2016, with the publication of Barry Greenberg and colleagues’ study,4 CUPID 2, we see that a principal limitation to cardiac gene therapy continues to be the inability to reliably transfer genes to the cardiac ventricles.

email